Tulsa Wealth Advisors INC Buys New Stake in DexCom, Inc. $DXCM

Tulsa Wealth Advisors INC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent filing with the SEC. The fund purchased 7,264 shares of the medical device company’s stock, valued at approximately $489,000.

Several other hedge funds have also bought and sold shares of DXCM. Reflection Asset Management purchased a new position in shares of DexCom during the fourth quarter valued at about $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom in the first quarter worth about $25,000. MCF Advisors LLC purchased a new stake in shares of DexCom in the fourth quarter worth about $32,000. Wellington Grp LLC lifted its position in shares of DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after buying an additional 475 shares in the last quarter. Finally, DV Equities LLC bought a new position in DexCom during the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares in the company, valued at $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total transaction of $358,576.00. Following the transaction, the executive vice president owned 100,361 shares in the company, valued at $7,326,353. This trade represents a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 99,794 shares of company stock worth $7,373,321. 0.28% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $89.75 on Monday. The business’s 50 day moving average is $76.08 and its two-hundred day moving average is $70.34. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $91.96. The stock has a market capitalization of $33.87 billion, a P/E ratio of 35.47, a PEG ratio of 1.51 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.48 earnings per share. As a group, research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Barclays restated an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Bank of America decreased their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Sanford C. Bernstein set a $77.00 target price on DexCom in a research report on Friday, May 1st. Weiss Ratings raised shares of DexCom from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.